Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial

@inproceedings{Emery2016EfficacyAS,
  title={Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial},
  author={Paul Emery and Roy M Fleischmann and Ingrid Strusberg and Patrick Durez and Peter Nash and Eric Jason B. Amante and Melvin Churchill and Won Yeul Park and Bernardo A. Pons‐Estel and Chenglong Han and Timothy A. Gathany and S. R. Xu and Yiying Zhou and Jocelyn H. Leu and Elizabeth C. Hsia},
  booktitle={Arthritis care & research},
  year={2016}
}
OBJECTIVE To evaluate the safety and efficacy of golimumab through 5 years in adults with active rheumatoid arthritis (RA) who had not previously received methotrexate (MTX). METHODS In the GO-BEFORE study, 637 MTX-naive adult patients with active RA were randomized (1:1:1:1) to placebo + MTX (group 1), golimumab 100 mg + placebo (group 2), golimumab 50 mg + MTX (group 3), or golimumab 100 mg + MTX (group 4). Inadequate responders in groups 1, 2, and 3 entered early escape at week 28 to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Similar Papers

Loading similar papers…